Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

European Electrotechnics updated its dividend policy

9/5/23 EELT

VK ID monthly active audience reached 91 mln users

9/5/23 VKCO

UWC reported for 6 months of 2023 under IFRS

9/5/23 UWGN

Medsi intends to enter markets in other countries

9/5/23 AFKS

SPB Exchange summarized the results of trading in August

9/5/23 SPBE

Moscow Exchange summarized the results of trading in August

9/4/23 MOEX

Number of investors has reached 34% of economically active population

9/4/23 MOEX

Rosseti started an additional share issue to acquire regional assets

9/4/23 FEES

VK Video platform is out of beta version

9/4/23 VKCO

Magnit opened the first kiosk GO at the railway station

9/4/23 MGNT